Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer acquires gene therapy developer Bamboo Therapeutics
Bamboo Therapeutics is engaged in the development of gene therapies for rare and devastating central nervous system and neuromuscular diseases In the first quarter of this year, Pfizer
Bamboo Therapeutics is engaged in the development of gene therapies for rare and devastating central nervous system and neuromuscular diseases In the first quarter of this year, Pfizer
The agency is expected to take a decision by early 2017. Spherotide is a generic version of the drug marketed under the names Decapeptyl/ Trelstar/Pamorelin with formulation for controlled release.
Zepatier is a once-daily, fixed-dose combination tablet that features the NS5A inhibitor elbasvir (50mg) and the NS3/4A protease inhibitor grazoprevir (100mg). The tablet’s efficacy and safety were assessed
The gene and cell therapy group recently established and commissioned a second specialist bioprocessing clean room suite at Harrow House and at its new laboratories at Windrush Court
The investment will go to sites at Barnard Castle, Durham; Montrose in Angus, Scotland; and Ware in Hertfordshire. At Barnard Castle, the company will spend £92m on a sterile facility to support the manufacture of
As per the agreement, the Chinese firm will buy all of the Gland Pharma shares owned by KKR Floorline Investments apart from the shares purchased from the company's other shareholders.
The company said treatment with its tau aggregation inhibitor had a marked beneficial effect on key measures of Alzheimer's disease in patients with mild or moderate forms of
Neurovance said that CTN was within the range of the pivotal trials of approved stimulants, with a 400 mg sample of the drug demonstrating an effect size of 0.6
The approval was granted after Teva agreed to divest more than 75 generic drugs to eleven companies. The divested products will include anesthetics, antibiotics, weight loss drugs, oral
The collaborative phase 1b/2 clinical trial will evaluate whether the combination is beneficial to ORR in patients diagnosed with High-Hyaluronan (HA) human epidermal growth factor receptor 2 (HER2)-negative